Cerebral elevation and accumulation of amyloid ␤-peptide is an invariant feature of Alzheimer disease. Results: Natural compound (20S)-Rg3, a PI4KII␣ activator, modulates ␥-secretase activity in lipid rafts by increasing levels of phosphoinositides. Conclusion: Activation of a key phospholipid synthetic pathway by a natural product regulates ␥-secretase activity. Significance: We identify a novel molecular mechanism for the regulation of ␥-secretase activity by (20S)-Rg3.
Elevation and accumulation of amyloid ␤-peptide (A␤) 3 in the brain are invariable events associated with Alzheimer disease (AD) (1, 2) . A␤ is produced by sequential proteolytic cleavages of the ␤-amyloid precursor protein (APP) by a set of membrane-bound proteases termed ␤-and ␥-secretases (3). Therapeutic strategies targeting AD currently under development include reducing A␤ generation, promoting A␤ clearance, and inhibiting A␤ aggregation (4) . Despite initial promise, the majority of these approaches suffered major setbacks in late stage clinical trials due to toxicity issues. Recent imaging studies revealed that extensive A␤ pathology precedes any detectable clinical symptoms by at least a decade (5) . Thus, early intervention is becoming increasingly important, and there is a significant unmet need for effective and safe prophylactic as well as therapeutic approaches in AD (6, 7) .
Cholesterol and a growing number of other lipids, such as phosphoinositides, have been extensively implicated in AD pathogenesis (8) . We have previously reported that phosphatidylinositol 4,5-bisphosphate (PI(4,5)P 2 ), a phospholipid that regulates key aspects of neuronal function (9) , is involved with cellular mechanisms underlying AD, such as the biogenesis of A␤ production as well as the synaptic action of A␤ (10, 11) . Cellular levels of PI(4,5)P 2 are inversely correlated with levels of secreted A␤ in cultured cells (10) . Conversely, overexpression of familial AD presenilin and APP mutants and exposure to A␤ oligomers caused a decrease in levels of PI(4,5)P 2 (10 -12) .
Synthesis of PI(4,5)P 2 in the brain is predominantly mediated by phosphatidylinositol-phosphate kinase type 1␥, which phosphorylates PI(4)P on the D-5 position of the inositol ring (9, 13, 14) . In mammalian cells, phosphatidylinositol (PI) 4-kinase generates PI(4)P, the main precursor for PI(4,5)P 2 (15) . PI4KII␣ is enriched in brain and has also been implicated in neurodegeneration (16, 17) . Overexpression of this enzyme was shown to promote the synthesis of PI(4)P as well as PI(4,5)P 2 , suggesting that PI4KII␣ may be the rate-limiting enzyme in PI(4,5)P 2 synthesis (18, 19) . Critically, PI4KII␣ was shown to localize subcellularly to lipid rafts (20, 21) , a major site of A␤ biogenesis.
The ␥-secretase is a membrane-embedded, multicomponent proteolytic enzyme consisting of four essential components, including PS1 or -2, nicastrin, Aph-1, and PEN-2 (3, 22) . Brain lipids have been shown to be essential for the reconstitution of ␥-secretase activity (23, 24) , and changes in lipid composition or membrane fluidity and thickness directly influence ␥-secretase activity (8, (25) (26) (27) (28) (29) , indicating that brain lipids are important regulatory factors for A␤ production. Several studies indicate that the presenilins, the catalytic components of the ␥-secretase complex, may be enriched in detergent-resistant membrane domains (DRMs), which are also referred to as lipid rafts (25, 26, 30) . Our previous study suggested that phosphoinositides may inhibit ␥-secretase activity by regulating the interaction between the lipid substrate and enzyme complex (27, 29) . Thus, it is conceivable that PI(4,5)P 2 influences the properties of the ␥-secretase by either modification of the lipid environment or sequestration of ␥-secretase component(s) in DRMs.
Natural compounds have been the basis for traditional remedies but also have been a major source for diverse drug leads for modern medicine (31, 32) . Natural compounds often produce cell or system level phenotypes via pleiotropic mechanisms, which may be ideal for the prevention and/or treatment of complex, chronic disorders, such as AD. However, elucidating the mechanisms of action for bioactive natural compounds has been one of the greatest challenges facing the field (33, 34) . Ginseng (Panax ginseng) is one of the most common ingredients in herbal medicine throughout the world and has been used to treat multiple ailments by people in Eastern Asia for thousands of years (35, 36) . Several studies indicate that ginseng improves memory and cognitive function in human (37, 38) . Cognitive benefits in AD in several human clinical trials have also been reported (39 -41) . Ginsenosides, the active components of ginseng, are triterpene glycoside compounds that exhibit structural variation (42) allowing for diverse biological activities, including antitumor (43) and neuroprotective activities (44) . More than 30 different ginsenosides have been identified to date, and a number of medical applications have been reported (35, 42) . Some ginsenosides have been shown to reduce the levels of A␤; however, the mechanism underlying A␤-lowering activity is not known (45, 46) .
In the present work, we identified a number of ginsenosides that have A␤-reducing activity, including (20S)-Rg3, a component of heat-processed ginseng. We investigated the mechanism underlying the A␤-reducing activity of (20S)-Rg3 and determined that it modulates the phosphoinositide synthetic pathway by increasing PI4KII␣ activity. Our work provides evidence that the activity/levels of PI4KII␣ and therefore modulation of PI(4)P and PI(4,5)P 2 levels in the neuronal membrane reduce A␤ biogenesis. Thus, our studies reveal a novel association of A␤-producing machinery and the phosphoinositide pathway.
EXPERIMENTAL PROCEDURES
Compounds-Individual ginsenosides were purified from white ginseng or heat-processed ginseng as described previously (47, 48) . Sulindac sulfide and naproxen were purchased from Biomol, and Compound E (49) was kindly provided by Dr. T. Golde (Mayo Clinic, Jacksonville, FL). All other chemicals were from Sigma-Aldrich and Bio-Rad except where indicated.
Cell Lines and Primary Neuron Cultures-CHO cells stably expressing wild-type human APP751 (CHO-APP) were provided by Dr. D. J. Selkoe (50) . These cells are the parental cell lines for all stably transfected CHO cell lines used in this study. 7WD4 cells were stably transfected with 10 g of each plasmid of wild-type PS1 using the SuperFect (Qiagen) transfection reagent according to the manufacturer's protocol. Individual Zeocin-resistant colonies were isolated and screened for PS1 expression by Western blotting. Stable cell lines (CHO-APP/ PS1WT) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin in the presence of 250 g/ml Zeocin (Invitrogen) and 400 g/ml G418 (Calbiochem). For transient transfection, cells were transfected in 100-mm dishes with 10 g of plasmid, and protein expression was verified after 24 h by Western blotting. For drug treatments, serum-containing medium was changed to a reduced serum medium (Opti-MEM, Invitrogen) containing a 50 M concentration of each compound. Stable PS1 Neuro2a APPsw transfectants were kindly provided by S. H. Kim and S. Sisodia (University of Chicago). Primary hippocampal cultures were prepared from 1-day-old B6SJLF1/J mouse pups as described previously (11) . Cells were grown in Eagle's minimum essential medium supplemented with 10% heat-inactivated fetal calf serum, 45 mM glucose, 1% Eagle's minimum essential medium vitamin solution, and 2 mM glutamine. After 24 h, this medium was replaced by Neurobasal A medium supplemented with 2% B27 nutrient mixture, 1% heatinactivated fetal calf serum, 0.4 mM glutamine, and 6.6 ng/ml 5-flurodioxyuridine and 16.4 ng/ml uridine to suppress cell division. To prevent the induction of plasticity by spontaneous synaptic activity, kynurenic acid (0.5 mM) was also included in the culture medium.
Analyses of A␤ and APP-Quantitation and detection of all A␤ species were performed using either Western blot analysis or sandwich ELISA (Invitrogen). Media were collected after 6 -8 h of drug treatment, and cell debris was removed by centrifugation. Conditioned media (1.0 ml) were incubated at 4°C overnight with 7N22 (1:500; Invitrogen) in a rotator. Protein G Plus/A-agarose beads (Calbiochem) were added, and rotational incubation was continued for an additional 4 h. The beads were then washed twice with ice-cold immunoprecipitation buffer (0.1% Triton X-100, 140 mM NaCl, 0.025% sodium azide, 10 mM Tris-HCl, pH 8.0; Ref. 84 ) and once with 10 mM Tris-HCl, pH 8.0 containing 0.025% sodium azide. Samples were collected by centrifugation at 8,000 ϫ g for 2 min using Spin-X (Costar). Samples were resolved by Tricine/urea gels (85) and subjected to Western blot analyses using 6E10. A␤ sandwich ELISA was performed using commercial A␤40 and A␤42 ELISA kits (Invitrogen) according to the manufacturer's protocol. Full-length APP was detected by Western blot analysis using the APPCTmax antibody (10) . Media were collected after 8 h of treatment, and cell debris was removed by centrifugation. A volume of 400 l of conditioned medium was immunoprecipitated with 7N22 (for ␣-secretase-derived soluble APP (sAPP␣); Invitrogen) and 800 l of medium with s␤WT (for ␤-secretase-derived soluble APP (sAPP␤)). s␤WT antibody was described previously (51) . Briefly, the antibody was generated by immunizing rabbits with keyhole limpet hemocyanin-conjugated peptides corresponding to the C-terminal region of secreted APP␤, (C)GGGISEVKM. An additional cysteine residue, indicated as (C), was inserted as a spacer. Samples were separated on Tris/ glycine gels (4 -20%). Either sAPP␣ or sAPP␤ was detected by Western blot analysis using LN27 (which recognizes the first 200 amino acids in APP N terminus; Invitrogen).
Lipid Raft Fractionation-CHO-APP/PS1 and brain tissue from APP/PS1 mice 65 were used for isolation of lipid rafts as described previously (26) with minor modifications: Lubrol WX was replaced with Brij98, the homogenization step was skipped, and different discontinuous sucrose gradient steps were performed (5-40%). Cells grown to confluence in two 150-mm dishes were washed twice with ice-cold phosphate buffer saline and scraped into 1 ml of lysis buffer (1% Brij98 in 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA) supplemented with a protease inhibitor tablet (Roche Applied Science), and lysates were incubated at 37°C for 10 min. Solubilized cell lysate was then adjusted to contain 40% sucrose by the addition of an equal volume of 80% sucrose in lysis buffer and transferred to a 12-ml ultracentrifuge tube. A discontinuous sucrose gradient was then formed by the addition of 35% sucrose (6 ml) and 5% sucrose (4 ml) and centrifuged at 39,000 rpm for 18 h in an SW41 rotor (Beckman) at 4°C (fraction 1 (top) to fraction 12 (bottom)). Twelve 1-ml fractions were collected starting with the top of the gradient, and equal volumes of each fraction were analyzed by Western blotting.
Immunocytochemistry-CHO-APP-PS1WT cells were transiently transfected with GFP-PI4KII␣. After an overnight incubation in the presence or absence of (20S)-Rg3, cells were fixed in 4% paraformaldehyde, permeabilized, and blocked for 1 h in 10% normal goat serum. Primary antibodies (PS1-NT and flotillin-1) were diluted in 10% normal goat serum containing 0.2% Triton X-100 and incubated overnight at 4°C. Organelle localization was detected using anti-flotillin-1 (BD Biosciences). Following incubation of primary antibody, cells were washed and incubated for 1 h at room temperature with Alexa Fluorconjugated secondary antibody (Invitrogen). Immunostained cells were mounted using Vectashield mounting medium (Vector Laboratories) and imaged using a Nikon C1 digital confocal system. Quantification analysis using ImageJ image analysis software was performed to measure the co-localization of PS1 or PI4KII␣ with flotillin-1. The percent co-localization was calculated as the area of the merged signal divided by the total area of the flotillin-1 signal in the image. This analysis was performed on 10 cells. The co-localization data sets of (20S)-Rg3-treated and non-treated cells were compared using Student's t test to measure statistical significance.
Lipid Analysis-The analysis of anionic phospholipid content of cells was carried out as described (11, 52) . Briefly, cells grown in 100-mm dishes were scraped into 0.75 ml of ice-cold MeOH, 1 M HCl (1:1) supplemented with 2 mM AlCl 3 . Lipids were then extracted and deacylated by incubation with 0.5 ml of methylamine reagent (MeOH, 40% methylamine in water, n-butyl alcohol, water (47:36:9:8)) at 50°C for 45 min. The aqueous phase was dried under N 2 , resuspended in 0.5 ml of n-butyl alcohol:petroleum ether:ethyl formate (20:40:1), and extracted twice with an equal volume of water. Aqueous extracts were dried, resuspended in water, and subjected to anion-exchange HPLC on an Ionpac AS11-HC column (Dionex). Negatively charged glycerol headgroups were eluted with a 1.5-86 mM KOH gradient and detected on line by suppressed conductivity in a Dionex ion chromatography system equipped with an ASRS ULTRA II self-regenerating suppressor. Individual peaks were identified, and peak areas were calculated using Chromeleon software (Dionex). Using deacylated anionic phospholipids as standards, lipid masses were calculated and expressed as molar fractions of total anionic phospholipids present in the sample.
Preparation of Lipid Kinases, Lipid Kinase Activity Assay, and Thin Layer Chromatography (TLC)-Stable PS1 Neuro2a APPsw cells cultured on 15-cm culture dishes were transfected with PI4KII␣ or the kinase-inactive mutant (D308A) of PI4KII␣ containing a C-terminal HA epitope tag (kindly provided by Dr. Tamas Balla, National Institute of Child Health and Human Development, National Institutes of Health; Ref. 18 ) for 48 h. Cells were lysed in 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM dithiothreitol, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, protease inhibitor tablet), and the lysates were cleared by centrifugation (14,000 ϫ g, 15 min). After preclearing with 20 l (1:1 slurry) of protein G Plus/A-agarose resin (Calbiochem) for 30 min, 10 g of monoclonal anti-HA antibody (MMS 101P, Covance) was added to the lysates, and the samples were incubated on a rotating platform at 4°C overnight. The antibody was then collected on 50 l of Protein G Plus/A-agarose resin, and the complex was washed three times with 1 ml of lysis buffer before a final wash in the PI kinase buffer. The enzyme was then analyzed by Western blotting, or its activity was assayed on the resin as described below. PIPK1␥90 was purified using glutathione-Sepharose resin (GE Healthcare) as described previously (53) . For the lipid kinase assay, stable PS1 Neuro2a APPsw cells were washed twice in ice-cold PBS, gently scraped, and centrifuged at 3,000 rpm (4°C, 5 min). Cell pellets were resuspended in 0.5 ml of HB buffer (250 mM sucrose, 5 mM Hepes, protease inhibitors) and centrifuged again at 3,000 rpm (4°C, 5 min). Cell pellets were resuspended in 0.125 ml of HB and homogenized by passing through a syringe/needle followed by centrifugation at 3,000 rpm (4°C, 5 min). 100 g of protein from the supernatant were used for TLC as described below. Either membrane preparations or partially purified kinase was mixed with 2.5 l of ATP (final concentration, 50 M), 2.5 l of CaCl 2 (final concentration, 50 M), 27.0 l of EGTA-free kinase buffer (25 mM Hepes, 100 mM KCl, 2.5 mM MgCl 2 ), and 0.5 l of [␥-
32 P]ATP (final concentration, 100 nCi/l), and samples were incubated at 37°C for 15 min. Reactions were stopped with 700 l of CHCl 3 : MeOH (2:1) supplemented with 10 g/ml brain-derived phosphoinositides. 400 l of 1 N HCl were added, and samples were vortexed 2 ϫ 10 s and centrifuged for 1 min at 10,000 rpm in a microcentrifuge. The organic phase was washed with 500 l of Neuronal Differentiation of Mouse Embryonic Stem (ES) CellsMouse ES cells that harbor the heterozygote knock-out of the PI4KII␣ allele (PI4KII␣ϩ/Ϫ, AD0414, and AC0537) and two wild-type (E14 p20 and nn13 p19) cell lines were purchased from Sanger Institute Gene Trap Resource. Direct differentiation of pyramidal neurons from ES cells was performed as described previously (54) with some modifications. ES cells were thawed and subsequently feeder cell-deprived for at least two passages in ES medium (DMEM, 15% ES grade FBS, nonessential amino acids, nucleosides, ␤-mercaptoethanol) supplemented with leukemia inhibitory factor (1,000 units/ml). Prior to plating, cell culture dishes were coated with 0.1% gelatin solution for at least 30 min. ES medium was changed every day. For embryoid body formation, 3 ϫ 10 6 ES cells were plated onto non-adherent bacterial dishes in EB medium (ES medium with only 10% FBS and without leukemia inhibitory factor) and cultured for 8 days. Medium was changed every 2 days, and 5 mM retinoic acid was added at day 4 for 4 days. Embryoid bodies were dissociated and plated on poly-D-lysine/laminin-coated dishes in N2 medium. Medium was changed after 2 h and again after 24 h. B27-containing differentiation medium was added after 48 h. Subsequently, B27 medium was changed every 2 days. At 8 days postplating, B27 medium was supplemented with ␤-mercaptoethanol (25 M). To measure changes in A␤ level, we used a lentiviral system for expression of APP. The Lenti-APPsw construct was made by PCR amplification followed by ligation into pLenti6/V5-D-TOPO (Invitrogen) using the manufacturer's protocol. The following primers were used for the amplification: APPLenti-F, 5Ј-CACCATGCTGCCCG-GTTTGGCACTGCTCCTGC-3Ј; APPLenti-R, 5Ј-GATATC-TCTAGTTCTGCATCTGCTCAAAGAAC-3Ј. This vector was co-transfected into HEK293 T cells with ViraPower packaging mixture (Invitrogen) to generate the lentivirus following the manufacturer's protocols. Differentiated ES cell-derived neurons on glass coverslips were fixed with 4% paraformaldehyde for 15 min. After removal of paraformaldehyde, three washes in PBS, and permeabilization with 0.2% (v/v) Triton X-100 for 3 min, cells were blocked in 10% normal goat serum for 3 h at room temperature. Cells were incubated with the primary antibody against neuronal ␤-tubulin (TUJ1, Covance) in 10% normal goat serum and PBS with 0.2% Triton X-100 overnight at 4°C. Detection was achieved using fluorescent Alexa Fluor (Invitrogen/Molecular Probes) secondary antibodies (1:500). Cell nuclei were stained with DAPI.
Compound Treatment for AD Mouse Models and A␤ Analysis of the Brain Tissue-The mice used were heterozygous, double transgenic animals expressing both human APP(K670N/ M671L) and PS1(M146L) proteins as described previously (55) . These Alzheimer disease model mice were age-matched (3 months old) in all experiments with wild-type littermates. Both sets of mice were produced by crossing heterozygous APP mice with heterozygous PS1 mice and were weaned at 3 weeks and genotyped by PCR of digested tail samples. (20S)-Rg3 was prepared in a saline solution containing 0.01% DMSO at a concentration of 10 mg/kg of body weight. This compound (or saline with 0.01% DMSO for controls) was administered daily via intraperitoneal injection. After sacrifice, one hemibrain from each mouse was frozen on dry ice, homogenized in sucrose buffer, and extracted via formic acid for A␤ quantification (86) using a commercial sandwich ELISA kit (Invitrogen). ELISA results are reported as the mean Ϯ S.D. in pmol of A␤/g of wet brain.
Expression and Purification of Recombinant PI4KII␣-Fulllength PI4KII␣ was expressed in Escherichia coli as a fusion product with glutathione S-transferase (GST) using pGEX-KG vector. The GST-PI4KII␣ fusion protein was generated using the EcoRI-StyI sites of the pGEX-KG vector, which contains human PI4KII␣ from pET-GST-PI4KII␣ (kindly provided by Dr. T. Balla). pGEX-KG vector was used as a GST control. GST fusion proteins were expressed in E. coli BL21(DE3). Cultures were grown in YTA medium (16 g/liter Tryptone, 10 g/liter yeast extract, 5 g/liter NaCl, pH 7.0) supplemented with ampicillin to an OD of 0.8 and induced overnight at 28°C by adding isopropyl 1-thio-␤-D-galactopyranoside to 1 mM. Cells were harvested and lysed in 25 ml of lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 10% glycerol, 5 mM DTT, 1 mM ATP, EDTA-free protease inhibitor tablet (Roche Applied Science))/1 liter of culture using a high pressure homogenizer (Emulsiflex C-5, Avestin). Triton X-100 was added to 1% to the lysate at this stage. Lysates were cleared by centrifugation (MLA-80, Beckman) at 50,000 rpm (20 min, 4°C) and applied to a 5-ml glutathione-Sepharose column (GSTrap HP, GE Healthcare). The column was washed with 10 column volumes of lysis buffer with 500 mM NaCl and 1 mM DTT (no ATP) followed by 10 column volumes of lysis buffer with 150 mM NaCl and 1 mM DTT (no ATP). Protein was eluted using a gradient of 1-50 mM glutathione in lysis buffer with 1 mM DTT and no ATP. Aliquots of the resulting fractions were subjected to SDS-PAGE under denaturing conditions. The fractions containing GST-PI4KII␣ were pooled and kept frozen at Ϫ80°C.
Reconstituted ␥-Secretase Assay-The ␥-secretase assay was performed as described previously (27, 29) . Membrane fractions isolated from CHO cells were solubilized with 1% CHAPSO and cleared by centrifugation at 100,000 ϫ g for 1 h. The resulting supernatant was incubated with 100 nM C99-FLAG substrate for 4 h in the presence of the indicated phos-pholipids. A␤40 and A␤42 were visualized by Western blot analyses using BA27 and BC05 antibodies, respectively.
Statistical Analysis-Statistical analyses were performed using Student's t test by comparison with control (DMSO) data. Data are presented as means Ϯ S.D. Data for each condition were acquired from at least three independent experiments.
RESULTS

Identification of (20S)-Rg3 as an A␤-lowering Natural
Compound-We initially tested a number of natural products for their ability to reduce A␤42 production. We treated CHO cells stably expressing human wild-type APP (CHO-APP) (10) with the extracts prepared from either unprocessed ginseng ("ginseng extracts"), heat-processed ginseng extracts, or chromatographic fractions (fractions 1 and 2) enriched with ginsenosides (bioactive components of ginseng extracts) prepared from heat-processed ginseng (Fig. 1A) . Historically, prior to ingestion, ginseng roots are often subjected to heat processing, which leads to changes in the chemical structure of active components, resulting in enhanced pharmacological activity and reduced toxicity (56) . We found that extracts and one of the fractions prepared from heat-processed ginseng, but not the extracts from unprocessed ginseng, reduced the secretion of A␤42 (Fig. 1A) . To further identify the active compound(s) responsible for the A␤42-lowering activity, we next tested the effects of individual ginsenosides on A␤ production. The ginsenosides are a family of active components of ginseng that differ by the side chain and sugar moiety attached to a common structural backbone (see Table 1 for chemical structures). We found that several ginsenosides, including 20R and 20S epimers of Rg3, Rk1, and Rg5, inhibited the secretion of A␤42 (Fig. 1B) . Other ginsenosides, including Rb1, Rb2, Rc, Rd, Re, Re, Rg1, and Rg2, had no significant effect on A␤ secretion in the CHO cells (Fig. 1C) .
We selected (20S)-Rg3 for further mechanistic studies (Fig.  1D ) because this compound was one of the most potent ginsenosides among the tested compounds (Fig. 1B) and is also relatively abundant compared with other trace ginsenosides present in heat-processed ginseng (ϳ3.6%, w/w; Ref. 57) . In these cells, (20S)-Rg3 lowered A␤42 more potently than A␤40 in a dose-dependent manner (Fig. 1E ). A␤40-reducing activity was observed only at higher concentrations. (20S)-Rg3 treatment did not affect the steady-state levels of full-length APP (Fig. 1, F  and G) . In contrast, levels of the C-terminal APP fragments Ginsenosides differ at their three (or two) side chains attached to the common triterpene backbone known as dammarane. The common structure skeleton for each group of ginsenosides is shown at left. CHO-APP cells were treated with the indicated ginsenosides and analyzed for A␤42 as described in Fig. 1 under the condition of 50 M, 8-h treatment. Based on the results of three independent experiments, ginsenosides that harbor A␤42-lowering activity are indicated as either Yes or No. Ginsenosides that affected cell viability at 50 M are indicated by (a). Glc, D-glucopyranosyl; Ara (pyr), L-arabinopyranosyl; Ara (fur), L-arabinofuranosyl; Rha, L-rhamnopyranosyl; Xyl, were up-regulated by the treatment. The levels of secreted soluble APP ectodomains resulting from either ␣-or ␤-secretasemediated APP cleavages (sAPP␣ or sAPP␤) were not affected by the (20S)-Rg3 treatment (Fig. 1, F and G) .
Effects of (20S)-Rg3 on A␤ Generation in Cultured Primary
Neurons-To validate the A␤-reducing activity of (20S)-Rg3 in neurons, we next tested its effectiveness in cultured hippocampal neurons derived from Tg2576 mice (58) expressing the Swedish familial AD mutant form of human APP. Treatment of these neurons with (20S)-Rg3 led to the inhibition of both A␤40 and A␤42 secretion in a dose-dependent manner ( Fig. 2A) . In contrast to the results obtained from cell lines (Fig. 1E) , the A␤-lowering potency was similar for both the A␤40 and A␤42 species. (20S)-Rg3 treatment did not lead to changes in the steady-state levels of full-length APP, sAPP␣, or sAPP␤ (Fig.  2B) . The C-terminal fragments were elevated in the samples from neurons treated with (20S)-Rg3, suggesting a potential involvement of ␥-secretase inhibition in the A␤-lowering effects of (20S)-Rg3.
Effects of (20S)-Rg3 on the Generation of Intracellular Domains (ICDs) from Notch and p75NTR-In addition to its
role in A␤ biogenesis, ␥-secretase mediates the intramembrane cleavage of other cellular substrates (e.g. Notch, ErbB4, and p75 neurotrophin receptor; for a review, see Ref. 59 ).
Using a cell-free ␥-secretase assay, we tested whether (20S)-Rg3 affected other ␥-secretase substrates. ␥-Secretase-mediated intramembrane cleavage of Notch1 or the p75 neurotrophin receptor to yield Notch1 or p75 neurotrophin receptor intracellular domains (NICD or p75-ICD, respectively; Refs. 60 and 61) was also unaffected by treatment with (20S)-Rg3 (Fig.  3) . Under these conditions, a ␥-secretase inhibitor, Compound E (49), effectively inhibited cell-free generation of NICD or p75-ICD, whereas sulindac sulfide, an A␤42-lowering nonsteroidal anti-inflammatory drug (63), did not affect ICD generation (Fig.  3) . Accordingly, it is plausible that normal physiological pathways that require ␥-secretase processing of these substrates are not likely to be adversely affected by (20S)-Rg3 treatment.
(20S)-Rg3 Reduces the Association of PS1 with Lipid RaftsLipid rafts are DRMs that consist of a characteristic subset of lipids and proteins (64) . Abundant evidence indicates that the majority of components in amyloidogenic APP processing machinery, including BACE1 and PS1, are enriched in biochemically isolated DRMs (25, 26, 30, (65) (66) (67) . Given the predicted lipophilic nature of the steroidal triterpene structure of (20S)-Rg3 (Fig. 1D) , we suspected that (20S)-Rg3 may modulate ␥-secretase activity by influencing the membrane environment (e.g. lipid rafts). To detect the raft-associated pool of PS1 and other ␥-secretase components, we first performed biochemical analyses of PS1-harboring DRMs (25, 26, 30) . It has been shown that the association of PS1 with lipid rafts is differentially sensitive to detergents, such as Triton X-100 and Lubrol WX (26) . Although Lubrol WX was found to be an optimal detergent for the isolation of PS1-bearing DRMs, it is no longer commercially available. We therefore tested a number of alternate detergents for their ability to separate PS1-enriched DRMs by density gra- -ICD) . Membrane fractions isolated from 293 cells expressing either Notch-⌬E (upper) or p75-⌬E (lower) were incubated in the presence of the following compounds: Compound E (Cpd.E; general ␥-secretase inhibitor), sulindac sulfide (SS; an A␤42-lowering nonsteroidal anti-inflammatory drug), and (20S)-Rg3. p75-ICD was detected using antibodies raised against its cytoplasmic domains, and NICD was detected using a cleavage site-specific NICD antibody. Very low amounts of NICD and p75-ICD were detected in starting material (Control) or in samples treated with Compound E. Generation of NICD and p75-ICD was preserved in samples incubated with DMSO, (20S)-Rg3, and sulindac sulfide. dient centrifugation (data now shown) and identified Brij98 as an optimal detergent that could efficiently separate PS1-harboring lipid rafts (Fig. 4A) . Both PS1 C-and N-terminal fragments, which are active forms of the ␥-secretase complex (68), were detected in fractions positive for the raft maker flotillin-1 (Fig. 4A) . Full-length and C-terminal fragments of APP as well as mature forms of nicastrin and PEN-2 were also detected in the lipid raft fractions (Fig. 4C) . In cells treated with (20S)-Rg3, we found that the levels of lipid raft-associated PS1 C-terminal fragments (CTF) and -NTF were significantly reduced (Fig. 4,  B-E) , whereas the levels of the corresponding fragments in total cell extracts remained unchanged (Fig. 4C) . We next performed confocal microscopy to assess the subcellular distribution of PS1 and the lipid raft marker flotillin-1 in intact cells. PS1 and flotillin-1 substantially co-localized in puncta throughout the cytoplasm (Fig. 4F) . Treatment of cells with (20S)-Rg3 decreased the co-localization of PS1 with flotillin-1 (Fig. 4G and Ref. 69 ). In contrast, co-localization of PI4KII␣, another raftassociated protein, with flotillin-1 was not affected by (20S)-Rg3 treatment (data not shown). Collectively, these data suggest that (20S)-Rg3 causes the redistribution of PS1 from lipid rafts to a non-lipid raft membrane compartment.
(
20S)-Rg3 Reduces A␤ Levels and the Lipid Raft Association of PS1 in Vivo-
To test the effects of (20S)-Rg3 in vivo, we administered (20S)-Rg3 to a mouse model for A␤ pathology (APP/PS1 mouse) at 3 months of age, a stage at which the A␤ burden is significant (55, 70) . APP/PS1 mice were treated with (20S)-Rg3 once a day for 4 weeks by intraperitoneal injection (10 mg/kg/ day). A␤ ELISA analysis of brain tissues revealed that (20S)-Rg3 treatment resulted in a significant reduction of A␤40 and A␤42 in the brain (Fig. 5, A and B) , indicating that (20S)-Rg3 harbors A␤-lowering activity in vivo. To evaluate the effects of (20S)-Rg3 on the association of PS1 with lipid rafts in vivo, forebrain samples from (20S)-Rg3-treated or control APP/PS1 mice were subjected to lipid raft fractionation. Both PS1 C-and N-terminal fragments were detected in the lipid raft fractions (Fig. 5C) . The levels of lipid raft-associated C-and N-terminal PS1 fragments were substantially reduced in the samples from the (20S)-Rg3-treated groups compared with controls (Fig. 5D) .
Modulation of Phosphoinositide Metabolism by (20S)-Rg3
It has been reported previously in the literature that ginsenosides regulate the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB; also called AKT) pathway (71-74), suggesting a possible link between (20S)-Rg3 and phosphoinositide regulation. To explore the possible lipid-modulatory role of (20S)-Rg3, we examined the steady-state anionic phospholipid profile using conductance-based HPLC analysis (11, 12, 52) . We found that treatment of mouse cortical neurons with (20S)-Rg3 led to increased levels of both PI(4)P and PI(4,5)P 2 (Fig.  6A) . In contrast, the levels of other phospholipids, such as phosphoinositol, diphosphatidylglycerol, and phosphatidylserine, were not affected. We next performed a lipid kinase activity assay using a detergent extract and [␥-32 P]ATP followed by TLC analysis to determine whether (20S)-Rg3 influences the formation of PI(4)P and/or PI(4,5)P 2 (Fig. 6, B and C) (10) . Treatment of the cells with (20S)-Rg3 significantly enhanced the incorporation of radiolabeled phosphate into both PI(4)P and PI(4,5)P 2 , indicating that (20S)-Rg3 increases the formation of both PI(4)P and PI(4,5)P 2 .
(20S)-Rg3 Potentiates the Activity of PI4KII␣-Because (20S)-Rg3 led to increased steady-state levels and synthesis of both PI(4)P and PI(4,5)P 2 , we hypothesized that the compound may modulate the activity of a PI lipid kinase (e.g. PI 4-kinase and/or PI 5-kinase) that mediates the formation of PI(4)P , the ratelimiting precursor of PI(4,5)P 2 synthesis (13, 15) . Among three known isoforms of PI 4-kinases, we particularly focused on the type II␣ PI 4-kinase (PI4KII␣) because PI4KII␣ is enriched in the brain and has been shown to undergo palmitoylation and localize to lipid rafts where a significant pool of PS1 is concentrated (20, 21, 75) . PI4KII␣ and PS1 fragments co-localized in the DRM fractions (Fig. 4A) . Because overexpression of PI4KII␣ was shown to promote the synthesis of PI(4)P as well as PI(4,5)P 2 (18), we attempted to determine whether overexpression of PI 4-kinase and subsequent increases in PI(4)P and PI(4,5)P 2 could recapitulate the effects elicited by (20S)-Rg3 treatment. Constructs encoding either mammalian wild-type (II␣) or the kinase-dead mutant (II␣-KD) forms of PI4KII␣ (HA-tagged) were transfected into stable PS1 Neuro2a APPsw cells. The expressed enzyme was immunoprecipitated using anti-HA affinity beads from cell extracts. Equal amounts of purified PI4KII␣ and PI4II␣-KD were subjected to the lipid kinase activity assay using PI as a substrate followed by TLC analysis (Fig. 6D) . PI4KII␣, but not the kinase-dead mutant version of this enzyme, induced the incorporation of [␥-32 P]ATP into PI(4)P as expected. Incubation of (20S)-Rg3 with the immunoprecipitated enzyme enhanced PI4KII␣ activity (Fig. 6 , D and E) in a dose-dependent manner (Fig. 6F) . In contrast, (20S)-Rg3 up to 50 M did not confer any detectable effects on the activity of PIPK1␥, a major brain PI(4)P 5-kinase (Fig. 6 , G and H) (75) (76) (77) . The (20S)-Rg3-induced increase in PI4KII␣ activity was also observed with recombinant PI4KII␣ (data not shown). Co-incubation of (20S)-Rg3 with PI4KII␣ and PIPK1␥ led to both PI(4)P and PI(4,5)P 2 formation, recapitulating the observed PI(4)P and PI(4,5)P 2 elevation in (20S)-Rg3-treated cells (Fig. 6, I and J) .
PI4KII␣ Overexpression Recapitulates the Effects of (20S)-Rg3-Because (20S)-Rg3 potentiates PI4KII␣ activity, we tested whether increasing PI4KII␣ activity through overexpression exerted similar effects on A␤42 generation as did (20S)-Rg3 treatment. A␤42 generation was significantly down-regulated in stable PS1 Neuro2a cells transiently transfected with constructs encoding HA-tagged PI4KII␣ (Fig. 7A) . The secreted A␤42 levels were also reduced in CHO cells stably expressing APP and transiently transfected with wild-type PI4KII␣ but not in cells transfected with the KD mutant form of PI4KII␣. This indicates that the catalytic activity of PI4KII␣ is required for the observed reduction in A␤42 generation (Fig. 7A) . In the PI4KII␣-overexpressing cells, the steady-state level of fulllength APP was not affected; however, we observed an increased accumulation of APP C-terminal fragments (Fig. 7B ) congruent with the effects of (20S)-Rg3 (Figs. 1F and 2B ).
We next determined whether increasing PI4KII␣ levels could influence the association of PS1 with lipid rafts. We found that overexpression of PI4KII␣, but not the KD mutant, reduced the association of PS1-CTF with the lipid raft fraction (Fig. 7, C, D , and E), indicating that PI 4-kinase activity is likely to be responsible for the changes in lipid raft localization of PS1. Collectively, our results suggest that both (20S)-Rg3 treatment and PI4KII␣ overexpression may modulate both A␤42 secretion and the association of PS1-CTF with lipid rafts through a mechanism involving PI4KII␣-mediated phosphoinositide modulation. Phosphoinositide Modulation of ␥-Secretase Activity-Our data support the model that (20S)-Rg3 mediates an increase in PI4KII␣ activity and a subsequent increase in PI(4)P and PI(4,5)P 2 levels. To examine the consequences of elevated PI(4)P and PI(4,5)P 2 on ␥-secretase activity, we next performed a ␥-secretase assay using CHO cell extracts in the presence of four different phosphoinositides (Fig. 8, A and B) (27) . The incubation of PI or phosphatidylcholine did not yield any detectable effects on the ␥-secretase-mediated generation of both A␤40 and A␤42 from the exogenous ␥-secretase substrate, C-terminal APP fragments. In contrast, A␤ generation was substantially reduced in the presence of PI(4)P and PI(4,5)P 2 .
PI4KII␣ Is Necessary for the A␤-lowering Activity of (20S)-Rg3-To further substantiate the role of PI4KII␣ in A␤ generation in neurons, we next used mouse ES cell-derived primary neurons harboring a heterozygous knock-out of the PI4KII␣ allele (PI4KII␣ϩ/Ϫ; obtained from Sanger Institute Gene Trap Resource). Pyramidal neurons were generated by directed differentiation of ES cells using a modified version of a published protocol (54) . The differentiation and morphology of pyramidal neurons from PI4KII␣ heterozygous (ϩ/Ϫ) ES cells were indistinguishable from neurons derived from wild-type ES cells (Fig.  9A) . Among several putative ES cell clones, we identified two clonal lines (AC0537 and AD0414) that expressed significantly reduced amounts of PI4KII␣ protein as detected by Western blot analysis (Fig. 9B) . The lipid kinase activity in homogenates from the differentiated pyramidal neurons revealed that both basal and (20S)-Rg3-augmented PI 4-kinase activity was significantly reduced in the heterozygous deleted lines (Fig. 9, C and  D) . Subsequently, the PI4KII␣ϩ/Ϫ neurons were infected with lentivirus carrying human APP harboring the Swedish mutation (Fig. 9B) to examine A␤42 generation. Secreted A␤42 levels were substantially elevated in neurons derived from PI4KII␣ϩ/Ϫ ES cells (Fig. 9E ) in contrast to the reduced A␤42 levels in PI4KII␣-overexpressing cells (Fig. 7A) . Thus, our data suggest that PI4KII␣ activity may be inversely correlated with A␤42 production in neurons. Importantly, the PI4KII␣ϩ/Ϫ ES cell-derived neurons did not exhibit the pharmacological response to (20S)-Rg3 and were no longer able to reduce A␤42 (Fig. 9E) , indicating that the A␤42-lowering activity of (20S)-Rg3 requires normal expression of PI4KII␣. These data further 
DISCUSSION
In the present study, we identified several triterpenoid natural compounds derived from heat-processed ginseng, including ginsenoside (20S)-Rg3, that reduced A␤ levels in cultured cell lines, neurons, and the brains of an AD mouse model. Our studies also provide evidence that activation of a lipid kinase, PI4KII␣, underlies the mechanism for the A␤-lowering activity of (20S)-Rg3. Thus, our study reveals a novel mechanism for ␥-secretase modulation by a small molecule activator of a key phospholipid synthetic pathway.
We showed that (20S)-Rg3 treatment can increase the levels of PI(4)P and PI(4,5)P 2 in cultured cells and enhance the activity of PI4KII␣ directly in a cell-free system (Fig. 6 ). Because PI(4)P is the rate-limiting substrate in the PI(4)P 5-kinase-mediated synthesis of PI(4,5)P 2 (18, 19) , (20S)-Rg3-evoked activation of PI4KII␣ in the presence of PIPK1␥ led to increased formation of both PI(4)P and PI(4,5)P 2 (Fig. 6, I and J) .
The changes in levels of PI(4,5)P 2 or PI(4)P can affect ␥-secretase activity through several different mechanisms. PI(4,5)P 2 has been shown to contribute to regulation of the lateral mobility of membrane proteins potentially in lipid rafts (78 -80) . Accordingly, PI(4,5)P 2 -evoked changes in the membrane lipid microenvironment may result in alterations in fluidity and thickness of the membrane, which are the parameters that influence properties of the ␥-secretase enzyme, including potency and substrate cleavage patterns (81, 82) . We showed that PI(4)P and PI(4,5)P 2 confer inhibitory effects on ␥-secretase-mediated generation of both A␤40 and A␤42 (Fig. 8) . Thus, changes in membrane composition by augmentation of PI(4)P and PI(4,5)P 2 decreased the ␥-secretase-dependent production of A␤, which is consistent with recent studies on the ␥-secretase activity dependence on the lipid environment (27) (28) (29) . Additionally, increases in PI(4,5)P 2 levels can recruit specific PI(4,5)P 2 -binding molecules to lipid rafts (78 -80) , which could subsequently influence the ␥-secretase activity. Because ginsenosides, including (20S)-Rg3, have steroid-like structures (Table 1) , these A␤-lowering ginsenoside compounds may promote the activity of PI4KII␣ by serving as membrane lipid mimics, thereby interacting with PI4KII␣ and stabilizing its structure. It is interesting to note that membrane cholesterol levels correlate with PI4KII␣ activity (20, 83) , and 25-hydroxycholesterol promotes PI4KII␣ activity (62) . Thus, it is conceivable that (20S)-Rg3 modulates PI4KII␣ in a manner similar to cholesterol-dependent regulation of PI4KII␣ activity and PI(4)P production. In addition to modulating phosphoinositide metabolism and A␤42 secretion, both (20S)-Rg3 treatment and PI4KII␣ expression reduced association of PS1 fragments, the catalytic components of ␥-secretase complex, with lipid raft fractions (Figs. 4  and 7) . (20S)-Rg3-induced reduction of PS1 fragments in lipid rafts is unlikely due to disruption of the integrity of lipid rafts because flotillin levels and PI4KII␣ association with rafts were not affected by the treatment. Because overall levels of PS1 fragments were not affected by (20S)-Rg3, the reduced association of PS1 fragments with lipid rafts and subsequent change in ␥-secretase activity in (20S)-Rg3-treated cells and brain tissue is likely due to redistribution of PS1 fragments from lipid rafts to a non-lipid raft membrane compartment.
